Scientists hunt for genetic signs that show which breast cancer patients will benefit from kisqali
NCT ID NCT05529862
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study collects tumor and blood samples from 241 women with HR+/HER2- advanced breast cancer before and after treatment with ribociclib (Kisqali) plus hormone therapy. Researchers will analyze DNA and RNA changes to find markers that predict who responds well and who develops resistance. The goal is to better understand why some patients benefit while others relapse, and to identify new drug targets for future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ribociclib (Kisqali) plus endocrine therapy
- What this could lead to
- If successful, this could help doctors predict which patients will benefit from ribociclib and endocrine therapy, and identify new treatment targets for those who don't respond.
- What could go wrong
- This is an observational, biomarker-focused study, not a treatment trial. It may not lead to immediate changes in patient care, and the findings might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC BREAST CANCER (BC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Paoli Calmettes
Marseille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common breast cancer drug work equally well in underrepresented groups?
- New drug targets Hard-to-Treat cancers in japanese patients
- Real-World study tracks palbociclib use in canadian breast cancer patients
- Gulf study reveals Real-World use of palbociclib for advanced breast cancer
- New drug combo for advanced breast cancer shows promise but trial halted early
- New blood test could personalize breast cancer care